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Context: Molecular diagnosis of congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deﬁciency (21OHD)
has not been straightforward.
Objective: To conduct a comprehensive genetic analysis by Multiplex Ligation dependent Probe Ampliﬁcation
(MLPA) and evaluate its reliability for the molecular CAH-21OHD diagnosis.
Patients andmethods:We studied 99 patients from 90 families with salt-wasting (SW; n = 32), simple-virilizing
(SV; n = 29), and non-classical (NC; n = 29) CAH-21OHD.Molecular analysis was sequentially performed by
detecting the most frequent point mutations by allele-speciﬁc oligonucleotide polymerase chain reaction
(ASO-PCR), large rearrangements by MLPA, and rare mutations by direct sequencing. Parental segregation
was evaluated.
Results: ASO-PCR detectedmicroconversions in 164 alleles (91.1%). MLPA identiﬁed CYP21A1P large conversions to
CYP21A2 in 7 of the remaining 16 (43.7%), 30-kb deletions including the 3′-end of CYP21A1P, C4B, and the 5′-end of
CYP21A2 in 3 of the 16 (18.7%), and a complete CYP21A2 deletion in one (6.3%). Five alleles (2.7%) required direct
sequencing; threemutations located in the CYP21A2 gene and two derived from CYP21A1Pwere found. No parental
segregationwas observed in patients with the c.329_336del and/or the CL6 clustermutations. These caseswere not
diagnosed by ASO-PCR, but MLPA detected deletions in the promoter region of the CYP21A2 gene, explaining the
genotype/phenotype dissociation.
Conclusion: Using the proposed algorithm, all alleles were elucidated. False-positive results in MLPA occurred
when mutations or polymorphisms were located close to the probe-binding regions. These difﬁculties were
overcome by the association of MLPA with ASO-PCR and paternal segregation. Using these approaches, we can
successfully use MLPA in a cost-effective laboratory routine for the molecular diagnosis of CAH-21OHD.© 2013 Elsevier B.V. All rights reserved.1. Introduction
Congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deﬁ-
ciency (21OHD) is an autosomal recessive disorder caused by an inborn
error of steroid metabolism and accounts for 90–95% of all CAH cases
(White and Speiser, 2000). The 21-hydroxylase enzyme is encoded
by the CYP21A2 gene located on chromosome 6 in a region knownOHD, 21-hydroxylase deﬁciency;
sting; SV, simple-virilizing; NC,
OHP, 17-hydroxyprogesterone;
peciﬁc oligonucleotide polymer-
obe Ampliﬁcation; RFLP, restric-
d; 3′UTR, 3′ untranslated; 30-kb
and 5′-end CYP21A2.
: +55 16 3633 6695.
.
rights reserved.as the RCCX module, which comprises the RP, C4, CYP21 and TNX
genes. There are three pseudogenes in the RCCX module, CYP21A1P,
TNXA, RP2, which are located between the two C4 loci. Because of the
high homology and tandem-repeat organization of the RCCX module,
this region of the genome is subjected to unequal crossover events lead-
ing to large rearrangements including duplications, deletions, and fusions
of the RCCX module (Yang et al., 1999).
Diminished or absent 21-hydroxylase activity leads to the reduction
or elimination of cortisol and aldosterone synthesis, accumulation of pro-
gesterone and 17-hydroxyprogesterone and shunting through the adre-
nal androgen biosynthetic pathway, which leads to overproduction of
adrenal androgens (White and Speiser, 2000). The spectrum of clinical
manifestations includes a severe, classical formwith two phenotypic clas-
siﬁcations, salt-wasting (SW) and simple-virilizing (SV), bothwith prena-
tal virilization of the external genitalia in female fetuses and postnatal
virilization in both sexes. There is also a mild, non-classical form (NC),
Table 1
Clinical and biochemical ﬁndings in patients with congenital adrenal hyperplasia due
to 21-hydroxylase deﬁciency.
SW (n = 32) SV (n = 29) NC (n = 29)
Median age 40 days
(1 to 180)
7 years
(0.3 to 17)
17 years
(3 months to 20.8 years)
Plasma Na (mEq/L) 130.5
(125.9–132.7)
139.0
(135.2–141.0)
140.0
(135.0–145.0)
Plasma K (mEq/L) 5.9
(5.6–6.5)
4.3
(3.7–5.0)
4.0
(3.5–4.5)
Plasma 17-OHP
(nmol/L)
584
(463.8–1135.8)
462.4
(335.5–774.7)
31.9
20.7–45.9
Plasma androstenedione
(nmol/L)
43.5
(41.4–140.8)
442
(257–1222)
4.8
(3.6–7.2)
Plasma testosterone
(nmol/L)
9.4
(7.9–14.8)
122
(83.6–252.3)
2.1
(1.8–3.7)
Plasma DHEAS
(nmol/L)
2.2
(1.6–3.4)
2.2
(1.5–3.6)
2.9
(2.0–5.2)
Prader classiﬁcation III to IV I to III Normal genitalia
All clinical and biochemicalﬁndingswere evaluated at diagnosis.Median (CI 95%). To convert
fromng/mLmultiply 3.026 for 17-OHP; 3.492 forΔ4-A; 3.576 for testosterone; and 0.002714
for DHEAS.
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childhood or puberty (Speiser et al., 2010; White and Speiser, 2000).
The establishment of genetic diagnosis of patients with CAH due
to 21OHD (CAH-21OHD) has not been straightforward. Screening
programs have indicated that the genetic diagnosis is a potentially
useful adjunct to hormonal measurements for the genetic counseling
of parents at the birth of a CAH child and of adolescents at the tran-
sition to adult care (Speiser et al., 2010). Finally, themolecular diagno-
sis of CYP21A2 mutations can be used in patients with the NC form of
CAH-21OHDwhose ACTH-stimulated 17-OHP levels are in the borderline
range of the heterozygote group (Speiser et al., 2010).
A complete characterization of the locus, including the number of
RCCX modules and the identiﬁcation of chimerical genes, has required
Southern blotting with probes for the different genes combined with
other techniques, such as the use of restriction endonucleases (Chang
and Lee, 2011). However, because this technique is labor intensive and
usually uses radioactive probes, alternative methods are being sug-
gested to substitute for Southern blotting in the molecular diagnosis
of CAH-21OHD. Multiplex Ligation dependent Probe Ampliﬁcation
(MLPA) has been used to assess gene copy number and to help identify
chimerical genes in patients with CAH-21OHD in a single experiment
without using radioactive probes (Chan et al., 2011; Chen et al., 2012;
Choi et al., 2012; Coeli et al., 2010; Concolino et al., 2009; Jang et al.,
2011; Kleinle et al., 2009; Schouten et al., 2002; Skordis et al., 2011).
However, the substitution of a methodological approach should not
hamper the reliability and cost effectiveness of the current tests.
In the present study, we conducted a comprehensive genetic analysis
to assess whether MLPA combined with allele-speciﬁc PCR (ASO-PCR)
and direct sequencing, in a sequential strategy, would provide reliable
genetic diagnoses.2. Materials and methods
2.1. Subjects
This studywas approved by the Institutional ReviewBoard for Human
Research, and written informed consent was obtained from all the pa-
tients or their parents (Protocol no. 701/2010).
We studied 99 patients (90 families) with CAH-21OHD, representing
180 unrelated affected alleles; we also studied all the available parents
to assess genetic segregation. In 82 families, there was 1 affected subject,
2 affected subjects in 7 families, and 3 affected subjects in 1 family. Fam-
ilies were divided into salt-wasting (SW; n = 32), simple-virilizing (SV;
n = 29), and non-classical (NC; n = 29) forms deﬁned according to
standard criteria (White and Speiser, 2000).
Table 1 shows the median and the conﬁdence interval (CI95%) of
age, sodium and potassium, 17OHP, androstenedione, testosterone,
and DHEAS plasma levels at the diagnosis of patients with SW, SV, and
NC forms of CAH-21OH. All patients with the NC form of CAH-21OH
showed ACTH-stimulated 17OHP levels greater than 1200 ng/dl or
36.4 nmol/L.2.2. Methods
2.2.1. Steroid determination
Blood samples were collected in heparinized tubes and immediately
centrifuged at 4 °C. Plasmawas kept frozen at−20 °C until assayed. Plas-
ma steroids were measured by speciﬁc radioimmunoassay as previously
described (Mermejo et al., 2005).2.2.2. Molecular analysis
Genomic DNA was obtained from peripheral blood by QIAamp DNA
blood kit (Qiagen, CA, USA). Molecular analysis was performed in three
sequential steps.2.2.2.1. Allele-speciﬁc PCR (ASO-PCR). ASO-PCR was performed using
eight primer pairs derived from the most frequent CYP21A1P muta-
tions (p.P30L, IVS2-13 A/C>G, c.329_336del, p.I172N, CL6, p.V281L,
p.R356W), as described (Wilson et al., 1995). The p.Q318X mutation
analysis was carried out by the PCR/RFLP (restriction fragment length
polymorphism) method (Dardis et al., 1997). Positive and negative
control DNAs were used in all reactions.
2.2.2.2. Multiplex Ligation dependent Probe Ampliﬁcation (MLPA).MLPA
was performed as recommended by the manufacturers using SALSA
MLPA P050B2 kits (MRC Holland, Amsterdam, Netherlands). The probe
mix comprises 33 different probes with ampliﬁcation products between
130 and 391 bp. These probes include: ﬁve speciﬁc probes for CYP21A2,
one located 18 nucleotides before exon 1 that recognizes the 5′UTR,
four probes recognizing the wild-type sequences for the c.329_336del,
p.I172N, cluster 6, and p.Q318X mutations positioned in the exons 3, 4,
6 and 8, respectively; three speciﬁc probes for CYP21A1P, three for TNXB,
one for C4A, one for C4B, three located on chromosome 6p21.3, one
Y-chromosome speciﬁc (UTY-gene) probe, and 16 probes as references.
Fragment analysis was performed on an ABI 3130 Genetic Analyzer (ABI
PRISM/PE Biosystems, Foster City, CA, USA), and the results were initially
analyzed using Genemapper v4.0 software (Applied Biosystems, Foster
City, CA, USA). Thereafter, data were normalized and analyzed using the
software Coffalyser v9.4 (MRC Holland, Amsterdam, Netherlands). This
program identiﬁes a sample peak as “normal” when the ratio of the
peak height of the sample to that of the control is between 0.8 and 1.2,
as “deleted” when the ratio is b0.8, and as “duplicated” when the ratio
is >1.2.
2.2.2.3. Direct sequencing. Two fragments ofCYP21A2, one of 600 bp from
the 5′UTR to exon 6 (CL6N) and the other from exon 6 (CL6N) to the 3′
UTR, were ampliﬁed. The fragments were directly sequenced with inter-
nal primers using BigDye™ Terminator Cycle Sequencing Kits V3.1 Ready
Reaction (ABI PRISM/PE Biosystems, Foster City, CA, USA). The se-
quences obtained with an ABI 3130 Genetic Analyzer (ABI PRISM/
PE Biosystems) were compared to CYP21A2 and CYP21A1P sequences
(Ensembl-ENSG00000231852 and ENSG00000204338, respectively)
using the software CodonCode Aligner (CodonCode Corporation,
Centerville, MA, USA).
2.2.3. Genotype categories
Patientswere divided into four different genotype groups, according
to the enzymatic activity impairment, as described by Speiser et al.
(1992) and modiﬁed by others (Krone and Arlt, 2009). The Null group
included patients who were homozygous for mutations that predict
Table 2
Frequency (%) of mutations in families with salt wasting (SW), simple virilizing (SV)
and non-classical (NC) forms of 21-hydroxylase deﬁciency evaluated by allele speciﬁc
oligonucleotide PCR (ASO-PCR).
Mutation Number of alleles % of alleles
SW SV NC Total SW SV NC Total
p.P30L 0 1 3 4 0.0 0.6 1.7 2.2
IVS2-13A/C>G 29 3 3 35 16.0 1.7 1.7 19.4
Δ8a 3 1 1 5 1.7 0.6 0.6 2.8
p.I172N 2 33 3 38 1.1 18.3 1.7 21.1
CL6b 1 1 1 3 0.6 0.6 0.6 1.7
p.V281L 1 2 41 44 0.6 1.1 22.8 24.4
p.Q318X 6 4 0 10 3.3 2.2 0.0 5.6
p.R356W 8 6 3 17 4.4 3.3 1.7 9.4
p.I172N + p.Q318X 0 1 0 1 0.0 0.6 0.0 0.6
p.Q318X + p.R356W 2 1 0 3 1.1 0.6 0.0 1.7
IVS2-13A/C>G + p.Q318X 0 2 0 2 0.0 1.1 0.0 1.1
IVS2-13A/C>G + p.R356W 1 0 0 1 0.6 0.0 0.0 0.6
IVS2-13A/C>G + p.V281L 1 0 0 1 0.6 0.0 0.0 0.6
ND alleles 10 3 3 16 5.6 1.7 1.7 8.9
Total 64 58 58 180 35.6 32.2 32.2 100.0
ND = not determined by ASO-PCR. Nomenclature according to http://www.cypalleles.ki.se/
cyp21.htm.
a Δ8 = 329_336delGAGACTAC.
b CL6 = cluster of p.I236N. p.V237E. and p.M239K mutations.
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conversion. Group A included patients with mutations that resulted in
0% to 1% of the 21OH enzymatic activity (IVS2-13 A/C>G). The Null
and A groups are associatedwith the SW form of CAH. Group B included
patients who were homozygous for p.I172N (1 to 5% of the enzymatic
activity) or harbored compound heterozygous mutations with the
p.I172N mutation and any other mutation from the Null or A group
and who were diagnosed with the SV form of CAH. Group C included
mutations with 20 to 50% of the 21OH enzymatic activity (p.V281L
and p.P30L) in homozygotes or in compound heterozygotes with any
other mutation from the Null or A or B groups.3. Results
Hyponatremia and hyperkalemiawere observed only in patients with
the SW formof 21OHD.We observed no difference in the levels of 17OHP
between the SW and SV forms, whereas androgen levels were higher in
the SW than in the SV form of 21OHD (p = 0.01). However, both groupsTable 3
Alleles determined by Multiplex Ligation Dependent Probe Ampliﬁcation (MLPA) in pati
21-hydroxylase deﬁciency.
Patients Number of gene copies detected by MLPA
CYP21A2 CYP21A1P CYP21A1P/CYP21A2
SW1 1 1 1
SW2 1 1 1
SW3 1 2 1
SW4 1 2 1
SW5 1 2 1
SW6 1 2 1
SW7 1 3 –
SW8 1 2 1
SW9 2 2 –
SW10 1 2 1
SV1 1 2 1
SV2 2 1 –
SV3 1 1 1
NC1 2 2 –
NC2 2 2 –
NC3 2 2 –
ND = not determined alleles.
a 30-kb del = deletion of 30 kb including 3′-end CYP21A1P and C4B and 5′-end CYP21A2
b LGC = large gene conversion.presented higher levels of 17OHP and androgens compared to the NC
group (p = 0.001).
The frequency of mutations derived from CYP21A1P in patients with
the SW, SV and NC forms of 21OHD was initially evaluated by ASO-PCR.
Using ASO-PCR, we found mutations derived from CYP21A1P in 164 out
of 180 alleles (91.1%), eight of themwithmore than one CYP21A1Pmuta-
tion (Table 2). The most frequent mutations were p.V281L (24.4%),
p.I172N (21.1%), and IVS2-13 A/C>G (19.4%). The p.V281L mutation
was observed in 70.6% of the patients with the NC form of CAH-21OHD,
while p.I172N and IVS2-13 A/C>G segregatedwith 56.8% of the SV form
and 45.3% of the SW form.
For the remaining 16 alleles (8.9%) not identiﬁed by ASO-PCR, we
performed MLPA analysis (Table 3). Of these 16 unidentiﬁed alleles, ten
were found in SW patients (SW-1 to SW-10), three in SV patients (SV-1
to SV-3) and three in NC patients (NC-1 to NC-3). Using the MLPAmeth-
od, we found a CYP21A1P large conversion to CYP21A2 in 7 of these 16
(43.7%), a deletion of 30-kb including the 3′-end of CYP21A1P and C4B,
and the 5′-end of CYP21A2 in 3 of the 16 (18.7%), and a complete
CYP21A2 deletion in one (6.3%) of the patients with alleles that had not
been previously identiﬁed by ASO-PCR. After ASO-PCR andMLPA studies,
ﬁve alleles (2.7%) had still not been identiﬁed, and we performed direct
sequencing analysis to identify them. We found ﬁve mutations, three
located in the CYP21A2 gene and two derived from CYP21A1P (Table 4).
Therefore, all alleles were identiﬁed using the sequential approach of
ASO-PCR, MLPA and direct sequencing, including alleles that were not
explained by parental segregation and had no genotype/phenotype
correlation.
Fig. 1A demonstrates an MLPA capillary electrophoresis pattern
obtained from one control subject (RCCX bimodular haplotype). As
can be observed, the ratio of the sample peak height to the control
peak height or area falls in the range of 0.8 to 1.2. Therefore, there
is an absence of deletions or duplications in the DNA in the HLA
class III region, which encodes three of four genes arranged in tan-
dem: C4, CYP21, and TNX. Fig. 1B shows the same data normalized
by the Coffalyser v9.4 (MRC Holland, Amsterdam, Netherlands).
Patient SW7 showed no parental segregation because he had a ho-
mozygous c.329_336del, but only his father presented with this mu-
tation (Table 3). There was no ampliﬁcation of the CL6 cluster in
this patient, whereas his parents showed the wild type CL6 cluster.
MLPA elucidated the genotype of this proband showing duplication
of CYP21A1P in the maternal allele (Fig. 2A).
Patient SV3 showed p.I172N/p.I172N, but her daughter had p.V281L/
p.V281Lwhen analyzed by ASO-PCR, suggesting a homozygousmutationents with salt wasting (SW), simple virilizing (SV), and non-classical (NC) forms of
Recombination breakpoint Genotype
in CYP21A1P/A2 chimeric gene
Exon 3/exon 4 IVS2-13A/C>G/30-kb dela
Exon 3/exon 4 IVS2-13A/C>G/30-kb dela
Exon 3/exon 4 p.R356W/LGCb
Exon 3/exon 4 IVS2-13A/C>G/LGCb
Exon 3/exon 4 p.Q318X/LGCb
Exon 1/exon 3 IVS2-13A/C>G/LGCb
– c.329_336del/CYP21A2 Deletion
Exon 3/exon 4 p.Q318X/LGCb
– IVS2-13A/C>G/ND
Exon 4/exon 6 IVS2-13A/C>G/LGCb
Exon 8/3′-end p.I172N/LGCb
– IVS2-13 A/C>G/ND
Exon 3/exon 4 p.I172N/30-kb dela
– p.V281L/ND
– p.V281L/ND
– p.V281L/ND
.
Table 4
Rare mutations observed in patients with salt wasting (SW), simple virilizing (SV) and
non-classical (NC) forms of 21-hydroxylase deﬁciency evaluated by direct sequencing.
21OHD formsa CYP21A2 genotype Nucleotide changeb
SW9 IVS2-13A/C>G/L307Frameshift c 920_921 insT
SV2 IVS2-13A/C>G/p.G424S c.1270G>A
NC1 p.V281L/p.P453S c.1357C>T
NC2 p.V281L/p.R408C c.1222C>T
NC3 p.V281L/p.A265V c.794C>T
a Patients as identiﬁed in Table 2.
b Nomenclature according to http://www.cypalleles.ki.se/cyp21.htm.
242 F.B. Coeli-Lacchini et al. / Gene 526 (2013) 239–245andnoparental segregation.MLPA analysis demonstrated that, in fact, the
SV3 patient presented a chimeric gene combining the promoter region of
CYP21A2 with part of CYP21A1P, which contains the c.329_336del muta-
tion in exon 3. Therefore, the genotype of the SV3 patient was correctly
ascertained as p.I172N/30-kb deletion. Her daughter, who had the NC
form of 21OHD, inherited from her mother the 30-kb deletion and from
her father the p.V281L allele (Table 3, Fig. 2B).
Patient SW6 showed the p.P30L (paternal allele)/IVS2-13A/C>G
(maternal allele); however, MLPA revealed a large gene conversion of
CYP21A1P and CYP21A2 between exon 1 and exon 3, comprising the
promoter region of CYP21A1P associated with p.P30L in the paternal al-
lele (Fig. 2C).
Patients SV1, SW1, SW2, SW3, SW4, SW5, SW8, and SW10 also
showed the p.P30L and, concurrently, other two mutations from
group A. These alleles would predict an NC form of 21OHD. MLPA eluci-
dated the genotype of these probands showing large gene conversions in
CYP21A1P and CYP21A2 or 30-kb deletions; the recombination breakpoint
of these hybrids occurred between exons 3 and 4 or between exons 4
and 6 (Table 3; Fig. 2D). Patients SW9, SV2, NC1, NC2, and NC3 each
showed one unidentiﬁed allele after the MLPA study. The alleles
were determined by direct sequencing to be c.920_921insT, c.1270G>A,
c.1357C>T, c.1222C>T, and c.794C>T, respectively (Table 4).Fig. 1.MLPA data from a normal control. (A) Capillary electrophoresis pattern. (B) Data norm
of 0.8 to 1.2. Probes 1 to 14 correspond to: (1) C4A exon 17; (2–4) CYP21A1P 5′ promoter reg
4, exon 6, and exon 8; (11–13) TNXB exon 32, 15, 1; and (14) CREB1. Probes 15 to 32 correRegarding the genotype/phenotype correlation, 29 of 32 SW fam-
ilies showed mutations classiﬁed as Null or A; however, the geno-
types of three patients (pV281L/p.Q318X, p.V281L/IVS2-13A/C>G,
and p.I172N/p.I172N) did not explain the phenotype. The DNA of
these three cases was analyzed by MLPA and direct sequencing, and no
large rearrangements or rare mutations were found. Thus, a genotype/
phenotype correlation was observed in 96.4% of the patients with the
SW form of CAH-21OHD.
Among29 familieswith the SV form, 23 showed the homozygousmu-
tation p.I172N or harbored compound heterozygous mutations including
the p.I172N mutation with another mutation from the Null or A group;
however, in six patients the genotype did not explain the phenotype;
two mutations (p.Q318X/p.Q318X and p.R356W/p.R356W) would pre-
dict the SW form, whereas four would predict the NC form because
p.V281L was found in one allele. The DNA of these six patients was ana-
lyzed by MLPA and direct sequencing, and no large rearrangements or
rare mutations were found. Thus, a genotype/phenotype correlation
was observed in 79.31% of the patients with the SV form of 21OHD.
Among29 familieswith theNC form, 13 showed thehomozygousmu-
tationp.V281L, 15 showedheterozygousmutations including thep.V281L
mutation together with another mutation from the Null or A or B group,
and one showed p.P30L/p.I172N. We observed genotype phenotype
correlations in all patients with the NC form of 21OHD. Therefore, the
absence of a genotype–phenotype correlation was observed in 4.6%,
18.2% and 0% of the patients with SW, SV and NC forms of CAH-21OHD,
respectively.4. Discussion
In the present study, we conducted a comprehensive genetic analy-
sis to assess the molecular diagnosis of patients with different forms of
21OHD.We conclude thatMLPA combinedwith ASO-PCR and direct se-
quencing, in a sequential strategy, can be used with high reliability for
the molecular diagnosis of 21OHD in a laboratory routine.alized by Coffalyser, the ratio of the sample peak height to the control falls in the range
ion, intron 2, 3′UTR; (5) C4B exon 19; (6–10) CYP21A2 5′ promoter region, exon 3, exon
spond to control probes, and probe 33 is the Y-chromosome speciﬁc probe.
Fig. 2.MLPAdata frompatients. Probes 1 to 14 correspond to: (1) C4A exon 17; (2–4) CYP21A1P 5′ promoter region, intron 2, 3′UTR; (5) C4B exon 19; (6–10) CYP21A2 5′ promoter region, exon
3, exon 4, exon 6, and exon 8; (11–13) TNXB exons 32, 15, and 1; and (14) CREB1. Columns correspond to integrated and normalized electropherogram peak areas, values between 0.8 and 1.2
indicate two copies, values less than 0.8 indicate one copy, and values above 1.2 indicate more than two copies. (A) Patient SW7 shows a homozygous bimodular haplotype with 3 copies of
CYP21A1P and 1 copy of CYP21A2 encompassing the 329_336delGAGACTAC mutation. (B) Patient SV3 shows a heterozygous mono/bimodular haplotype with one copy of CYP21A1P and
one copy of CYP21A2 encompassing the p.I172Nmutation and a chimeric gene combining the promoter region of CYP21A2with part of CYP21A1P, which contains the c.329_336del mutation
in exon 3. (C) Patient SW6 shows a homozygous bimodular haplotypewith a chimeric gene comprising a large conversion of CYP21A1P and CYP21A2 between exon1 and exon3 and two copies
ofCYP21A1P. The arrow indicates the reductionof probe4,whichmeans that oneof the twoCYP21A1P copies showsadeleted3′UTR sequenceor that this region is the same in theCYP21A2gene.
(D) Patient SW5 shows a homozygous bimodular haplotype with a large conversion of CYP21A1P and CYP21A2 between exons 3 and 4, two copies of CYP21A1P and 1 copy of CYP21A2
encompassing the p.Q318X mutation, which is indicated by the reduction of probe 10 (arrow). The increment of probe 1 indicates a putative C4A/C4B chimeric gene.
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work. Using ASO-PCR, we were able to diagnose 91.1% of the affected al-
leles. Indeed, point mutations have been found in 90 to 95% of the alleles,
most of them derived from the CYP21A1P. In addition, we found that the
most frequent mutations in the SW, SV and NC forms were IVS2-13A/
C>G (45.3%), p.I172N and p.V281L, respectively. Our study is in accord
with many other worldwide (Ezquieta et al., 1995; Mornet et al., 1991;
Speiser et al., 1992) and Brazilian (Bachega et al., 2000; de-Araujo et al.,
1996; Torres et al., 2003) studies. It is important to note that, in our series,
patients diagnosed by the ASO-PCR method were not studied by MLPA,and thus, we cannot rule out a CYP21A2 deletion/duplication associated
with point mutations in these patients.
For the remaining alleles not identiﬁed by ASO-PCR, we performed
MLPA analyses instead of Southern blots. We found CYP21A1P large
rearrangements with CYP21A2 in 62.5% of the alleles not initially identi-
ﬁed by ASO-PCR, corresponding to 5.5% of the total affected alleles. We
also found one patient with a complete CYP21A2 deletion, corresponding
to 0.5% of the total affected alleles. Among the subjects studied by MLPA,
no CYP21A2 duplication was found; signiﬁcant variations in gene copy
number and deletions of CYP21A2 comprised ~20% of the alleles (White
244 F.B. Coeli-Lacchini et al. / Gene 526 (2013) 239–245and Speiser, 2000). Previous data from Argentinean, Brazilian, and Mexi-
can patients with CAH have shown a lower frequency of the CYP21A2 de-
letion compared to the worldwide population (Bachega et al., 1999;
Dardis et al., 1997; Tusie-Luna et al., 1996).
The genotypes of patients with CAH due to 21OHD, whose alleles
appeared to be unexplained by parental segregation,were also elucidated
by MLPA associated with ASO-PCR. Patients SW7 and SV3 were homo-
zygous for c.329_336del/c.329_336del and p.I172N/p.I172N, respec-
tively, without parental segregation. Southern blots with radioactive
or nonradioactive probes have been used to verify the hemizygous
status in these cases. In the present study, using MLPA, we were able
to show that both patients were hemizygous due to mutations in the
CL6 cluster and the c.329_336del, using site speciﬁc primers to amplify
only the CYP21A2 gene. MLPA was also useful for elucidating the geno-
type of the SW7 proband, who showed a duplication of CYP21A1P in the
maternal allele, and the SV3 proband, who showed a chimeric gene
combining the promoter region of CYP21A2 with part of CYP21A1P
containing the c.329_336del mutation in exon 3.
The allelic heterogeneity of 21OHD underlies phenotypic heterogene-
ity. The SW6patient carries the p.P30L (paternal allele) and the IVS2-13A/
C>G (maternal allele), which would predict a nonclassical form of CAH;
however, MLPA revealed hybrids of CYP21A1P and CYP21A2 between
exon 1 and exon 3, comprising the promoter region of CYP21A1P associat-
ed with p.P30L in the paternal allele. Previous studies have shown dif-
ferences in the activity of the human CYP21A2 and CYP21A1P gene
promoters in steroidogenic cells (Kyllo et al., 1995). Thus, mutations
in this area, produced by the gene-conversionmechanism postulated
for the majority of the coding region mutations, could contribute to
the variable spectrum of disease presentation in 21OHD. The hybrid
with the promoter conversion associated with p.P30L had been pre-
viously described in another Brazilian proband (Araujo et al., 2007),
leading to a more severe phenotype than predicted by the genotype.
Furthermore, no phenotype–genotype correlation was observed in
patients with p.P30L and two other CYP21A2 mutations from group
A. These genotypes would predict an NC form of 21OHD; however,
these patients also showed a large conversion of CYP21A1P and CYP21A2
detected by MLPA, leading to the more severe form of the disease.
The MLPA probes c.329_336del, p.I172N, CL6 and p.Q318X cannot
distinguish between gene and pseudogene, in contrast to the ASO-PCR
(Wilson et al., 1995). In addition, false positive results occur in the pres-
ence ofmutations or polymorphisms located close enough to the probe-
binding regions to prevent probe hybridization and ligation (Concolino
et al., 2009). Thus, the interpretation of MLPA studies in 21OHD must
take into account some putative pitfalls. One pitfall could be the pres-
ence of a pseudogene that has the wild type allele for the p.Q318X mu-
tation. In this case, theMLPA results for this probe can be overestimated,
falsely indicating a duplication. Furthermore,when a patient is homozy-
gous for the p.Q318Xmutation in the active gene and is homozygous for
the wild type allele in the pseudogene, the MLPA results indicate a het-
erozygous genotype, contradicting the results obtained by ASO-PCR in
the active gene (Canturk et al., 2011). MLPA could also give false posi-
tive results when multiple heterozygous mutant peaks are detected,
the mutations can be either on separate chromosomes or on the same
chromosome. In this case, MLPA by itself cannot determine the geno-
type, and the association with ASO-PCR is mandatory, justifying the se-
quential protocol suggested by us.
In our series, following the ASO-PCR and MLPA steps, ﬁve alleles
remained unidentiﬁed andwere analyzed by direct sequencing. Fivemu-
tations were found including two mutations derived from CYP21A1P, the
p.P453S mutation, which reduces 21OH activity to 68% compared to the
wild type and has been reported to cause the NC form of 21OHD in differ-
ent populations (Balsamo et al., 2003; Lajic et al., 2002), and the L307
frameshift, which seems to be present in the pseudogene at a low
frequency (Wedell, 1998). In addition, we found three rare mutations
in the CYP21A2 gene. The ﬁrst, p.G424S, has previously been described
in Brazilian patients, segregating as a monomodular allele (C4A andCYP21A1P deletion), and it was observed in our patient, SV2 (Billerbeck
et al., 1999; Tardy et al., 2010). The second rare mutation, p.R408C, has
been associatedwith SW-CAHandwasdescribed in another twoBrazilian
population studies (Billerbeck et al., 2002; Soardi et al., 2008). The identi-
ﬁcation of one additional patientwith thismutation indicates that it is dif-
fusing in this population, consistent with the hypothesis of a founder
effect. The thirdmutation, p.A265V, with no signiﬁcant impact on protein
structure, was shown to result in enzyme activity similar to that of the
wild type enzyme (Bleicken et al., 2009); it is considered a verymildmu-
tation associated with NC-CAH. Such signiﬁcant residual activity may in-
dicate that this variant may only result in a clinical phenotype when in
combination with other unknown genetic factors rather than being the
single cause for an NC-CAH phenotype on its own (Bleicken et al., 2009).
Using the proposed algorithm for themolecular diagnosis of 21OHD,
we still observed the absence of genotype/phenotype correlations in
4.6% and 18.2% of the patients with SW and SV forms of 21OHD, respec-
tively. Occasional discrepancies between genotype and phenotype sug-
gest the effects of gene modiﬁers. Mutations in P450 oxidoreductase
(POR), the protein that transfers electrons from reduced nicotinamide
adenine dinucleotide phosphate to all microsomal P450s, can modulate
the 21OHDphenotype (Scott et al., 2007). In contrast, another study did
not ﬁnd POR variations that could explain discrepancies between the
21OHD phenotype and genotype (Gomes et al., 2009). Other genes in-
volved in androgen sensitivity or extra-adrenal 21OH activity may ac-
count for variations in the 21OHD phenotype. Controversial data have
been reported regarding the role of the number of CAG repeats in the
androgen receptor gene (AR) as a modiﬁer of the degree of genitalia
virilization in patients with 21OHD (Rocha et al., 2008; Welzel et al.,
2010). The extra-adrenal hydroxylation may also modulate the pheno-
type of patients with 21OHD. Gomes et al. (2009) found a homozygous
CYP2C19 ultrametabolizer allele in only one of ﬁve 21OHD patients
whose phenotypewas unexpectedlymild for the CYP21A2 genotype. Fi-
nally, some patients with severemutations do not have clinically signif-
icant salt loss, and other patients appear to regain their ability to retain
salt over time. Such recovery from salt lossmay reﬂect increased dietary
sodium, increased mineralocorticoid sensitivity, and increased activity
of other enzymes that can hydroxylate progesterone at the 21 position
(White and Speiser, 2000).
A weakness of the study is that no Southern blots were performed.
However, MLPA using small DNA samples and a nonradioactive probe,
when carefully interpreted, was a rapid, safe, and highly reliable meth-
od for the diagnosis of CAH due to 21OHD. We conclude that, using the
proposed algorithm,we can successfully elucidate all alleles from99 pa-
tients with classical and nonclassical forms of CAH due to 21OHD.
Therefore, the use of MLPA in association with ASO-PCR and paternal
segregation appears to be an effective laboratory routine in the molec-
ular diagnosis of CAH due to 21OHD.
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